RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Krystal Biotech Stock

Krystal Biotech Employees 2024

Krystal Biotech Employees

75

Ticker

KRYS

ISIN

US5011471027

WKN

A2JH2F

In 2024, Krystal Biotech employed 75 people, a 0% change from the 75 number of employees in the previous year.

Krystal Biotech Aktienanalyse

What does Krystal Biotech do?

Krystal Biotech Inc was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. The company specializes in the development and commercialization of gene therapy products. It has several divisions, including dermatological and musculoskeletal diseases, as well as Ebenezer and X-Linked Retinoschisis. In the history of the company, there have been several milestones. In 2017, the company completed its first financing round, raising $8 million. In the same year, it became the first company to successfully treat a patient with its gene therapy for epidermolysis bullosa. This was a major breakthrough as this disease is otherwise difficult to treat. In 2018, the company went public on the Nasdaq, raising over $50 million. In 2019, Krystal Biotech began developing a gene therapy product for hereditary angioedema. The company's business model is primarily based on the discovery and development of gene therapy products targeting genetic defects. The goal is to treat diseases that are otherwise difficult or impossible to treat. Krystal Biotech emphasizes that it follows a patient-centric approach in the development of its gene therapy products. Another part of the business model is collaborating with partner companies and institutions to advance the development and commercialization of its products. Krystal Biotech Inc has several divisions. The first division focuses on dermatological diseases. Its gene therapy products are designed to treat epidermolysis bullosa and Netherton syndrome. Epidermolysis bullosa is a rare disease caused by a mutation in collagen and other proteins, leading to blistering and lesions on the skin. Netherton syndrome is a disease that can also cause skin rashes and allergic reactions. Krystal Biotech offers gene therapy products to reduce the symptoms of these diseases and improve patients' quality of life. Another division is musculoskeletal diseases. Krystal Biotech Inc has developed gene therapy products to treat patients with osteoarthritis and sickle cell anemia. Osteoarthritis is a painful condition caused by the breakdown of cartilage in the joint. The gene therapy products offered by Krystal Biotech are intended to promote the regeneration of cartilage cells and support joint preservation. Sickle cell anemia is an inherited disease that causes red blood cells to have an abnormal shape and can block blood vessels. Krystal Biotech's gene therapy products are intended to reduce the risk of painful crises caused by this condition. Another division of Krystal Biotech is Ebenezer and X-Linked Retinoschisis. This is an inherited condition that affects vision. Krystal Biotech has developed gene therapy products to treat this problem. Overall, Krystal Biotech Inc has conducted promising research projects. The company has core expertise in gene therapy and can apply its innovations to various medical fields. The gene therapy products offered by Krystal Biotech are intended to improve patients' lives and treat diseases that are otherwise difficult to cure. Krystal Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Krystal Biotech's Employee Base

Krystal Biotech's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Krystal Biotech's operational capacity and future potential.

Year-to-Year Comparison

Assessing Krystal Biotech's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Krystal Biotech's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Krystal Biotech’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Krystal Biotech stock

How many employees does Krystal Biotech have this year?

Krystal Biotech has 75 undefined employees this year.

How many employees did Krystal Biotech have compared to the previous year?

Compared to the previous year, Krystal Biotech had 0% more employees.

What impact did the number of employees have on the company Krystal Biotech?

The number of employees has a direct impact on the efficiency and productivity of Krystal Biotech. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Krystal Biotech?

The number of employees can also have an impact on investors of Krystal Biotech, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Krystal Biotech affect the company?

An increase in equity of Krystal Biotech can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Krystal Biotech's equity affect the company?

A reduction in equity of Krystal Biotech can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Krystal Biotech?

Some factors that can influence the equity of Krystal Biotech include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Krystal Biotech so important for investors?

The equity of Krystal Biotech is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Krystal Biotech influence the company?

The number of employees at Krystal Biotech can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Krystal Biotech evolved in recent years?

In recent years, the number of employees at Krystal Biotech has changed by 0.

How many employees does Krystal Biotech currently have?

Krystal Biotech currently has 75 undefined employees.

Why is the number of employees important for investors of Krystal Biotech?

The number of employees is important for investors of Krystal Biotech as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Krystal Biotech take to change the number of employees?

To change the number of employees, Krystal Biotech can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Krystal Biotech pay?

Over the past 12 months, Krystal Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Krystal Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Krystal Biotech?

The current dividend yield of Krystal Biotech is .

When does Krystal Biotech pay dividends?

Krystal Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Krystal Biotech?

Krystal Biotech paid dividends every year for the past 0 years.

What is the dividend of Krystal Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Krystal Biotech located?

Krystal Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Krystal Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Krystal Biotech from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Krystal Biotech pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Krystal Biotech in the year 2023?

In the year 2023, Krystal Biotech distributed 0 USD as dividends.

In which currency does Krystal Biotech pay out the dividend?

The dividends of Krystal Biotech are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Krystal Biotech

Our stock analysis for Krystal Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Krystal Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.